NPS Pharmaceuticals, Inc. to Host Conference Call to Discuss FDA Approval of Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will host a conference call to discuss its commercialization plan for Gattex, including the cost of therapy, today at 5:00 p.m. Eastern Time. To participate in the conference call, dial (800) 706-7748 and use pass code 18085144. International callers may dial (617) 614-3473, using the same pass code. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar.